ORIGINAL ARTICLE: PDF OnlyPARNIS STEVEN M.; CONGER, JEFF L.; FUQUA, JOHN M. JR.; JARVIK, ROBERT K.; INMAN, REX W.; TAMEZ, DANIEL; MACRIS, MICHAEL P.; MOORE, SHEILA; JACOBS, GORDON; SWEENEY, MICHAEL J.; FRAZIER, O. H.ASAIO Journal: September-October 1997 - p M580 Free Abstract Development of the Jarvik 2000 intraventricular assist system for long-term support is ongoing. The system integrates the Jarvik 2000 axial flow blood pump with a microprocessor based automatic motor controller to provide response to physiologic demands. Nine devices have been evaluated in vivo (six completed, three ongoing) with durations in excess of 26 weeks. Instrumented experiments include implanted transit-time ultrasonic flow probes and dual micromanometer LV/AoP catheters. Treadmill exercise and heart pacing studies are performed to evaluate control system response to increased heart rates. Pharmacologically induced cardiac dysfunction studies are performed in awake and anesthetized calves to demonstrate control response to simulated heart failure conditions. No deleterious effects or events were encountered during any physiologic studies. No hematologic, renal, hepatic, or pulmonary complications have been encountered in any study. Plasma free hemoglobin levels of 7.0 ± 5.1 mg/dl demonstrate no device related hemolysis throughout the duration of all studies. Pathologic analysis at explant showed no evidence of thromboembolic events. All pump surfaces were free of thrombus except for a minimal ring of fibrin, (∼1 mm) on the inflow bearing. Future developments for permanent implantation will include implanted physiologic control systems, implanted batteries, and transcutaneous energy and data transmission systems. © Lippincott-Raven Publishers.